Speakers

Andrea Califano is the Clyde and Helen Wu Professor of Chemical and Systems Biology at 
Columbia University Vagelos College of Physicians and Surgeons, with cross-appointments in Biochemistry & Molecular Biophysics, Biomedical Informatics, and Medicine. From 2013 to 2023, he was the Founding Chair of the Department of Systems Biology and Director of the JP Sulzberger Columbia Genome Center. 
  
In 1986, after completing a doctoral thesis in physics at the University of Florence, Italy, and postdoctoral training at MIT, Califano joined the IBM TJ Watson Research Center, where, in 1997, he became program director of the IBM Computational Biology Center. In 2000, he co-founded First Genetic Trust Inc. to pursue translational genomics research. Finally, he joined Columbia in 2003. 
 
Califano is an internationally recognized pioneer in the reverse engineering and interrogation of gene regulatory networks. He has discovered a new class of Master Regulator proteins representing the regulatory bottleneck responsible for canalizing the effect of mutations and aberrant endocrine and paracrine signals into the transcriptional state of cancer cells. As a result, Master Regulators have emerged as highly conserved non-oncogene dependencies that are independent of the specific mutational landscape of different tumors in the same subtype. This novel discovery framework has helped elucidate key mechanisms underlying tumorigenesis and drug sensitivity and their translation has resulted in several clinical trials, from breast and pancreatic adenocarcinoma to neuroendocrine tumors, sarcomas, and glioblastoma, including an innovative N of 1 trial enrolling across 18 distinct malignancies. 
 
Califano is very active nationally, serving on numerous editorial and scientific advisory boards, including for The MIT Koch Cancer Center, Cancer Genetics Inc., Dana Farber Cancer Center, OHSU Brenden-Colson Center for Pancreatic Care, the WIN consortium, the German Cancer Center (DKFZ), DOE-NCI Cancer Moonshot project, as well as of the Pershing Square and Damon Runyon Foundations. He has served as chair or co-chair of many international conferences and meetings, including the annual meeting of the American Association for Cancer Research (AACR); the RECOMB-ISCB Conference on Regulatory and Systems Genomics, with DREAM Challenges; Keystone Conferences; as well as several special conferences of the AACR on genomics and cancer systems biology.   
 
Califano has received several awards and recognitions, including the 2015 and 2022 NCI 
Outstanding Investigator Award, the 2019 Ruth Leff Award in Pancreatic Cancer, and the 2023 NCI Alfred G. Knudson Award in Cancer Genetics. He is a member of the National Academy of Medicine and a Fellow of the AAAS, the International Society of Computational Biology, and the IEEE; he is also co-founder of DarwinHealth Inc. He is also a Fellow of the American Association for Cancer Research Academy. 

Bertha Coombs is CNBC’s senior health care reporter, covering health care services and policy, as well as financial markets and business news stories throughout the business day. 

Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act, the evolution of health care technology, and the continuing push to disrupt pharmacy models and lower drug costs, to the launch of the IRA Medicare drug price negotiations. 

Over twenty years at CNBC, Coombs has covered the tech sector from the Nasdaq Marketsite and general market news from the floor of the New York Stock Exchange.  Before joining the network, she reported for the pioneering streaming business network, Yahoo Finance Vision. Prior to that, she served as a reporter for ABC News One and a substitute anchor for “World News Now” and “World News This Morning.”  She began her reporting career in local news as a Leo Beranek Fellow at WCVB-TV in Boston. 

Coombs is a graduate of Yale University. Born in Havana, Cuba, she speaks fluent Spanish. 

John D’Angelo, MD, is the President of Northwell’s Central Region, which includes North Shore University Hospital, Long Island Jewish Medical Center, Cohen Children’s Medical Center, LIJ Forest Hills Hospital, LIJ Valley Stream Hospital and Zucker Hillside Hospital, as well as Northwell’s 120+ ambulatory locations within the Nassau/Queens area. 

Additionally, Dr. D’Angelo serves as Northwell’s Chief of Integrated Operations. In this role, Dr. D’Angelo leverages the lessons learned in the COVID-19 response to seamlessly integrate Northwell’s extensive operational resources in the post-pandemic era.  

Throughout 2020 and 2021, Dr. D’Angelo was the Operations Chief for Northwell’s COVID-19 command center, managing Northwell’s operational response to the pandemic. 

Previously serving as Senior Vice President and Executive Director of Northwell Health’s Emergency Medicine Service Line, Dr. D’Angelo was responsible for the clinical and operational performance of Northwell Health’s emergency departments, hospital-based observation units, and a rapidly expanding network of urgent care centers; an operation that serves nearly 1.5 million patients annually. 

As an Emergency Medicine physician for over 25 years, Dr. D’Angelo has a keen understanding of clinical care delivery, quality, process improvement and operations management. He has spearheaded numerous initiatives that have distinguished Northwell over the years. Examples of his work include Northwell’s sepsis efforts, which earned The Joint Commission’s Eisenberg Award, the opening of Manhattan’s first free-standing emergency department, Lenox Health Greenwich Village, and the accreditation of Northwell’s emergency departments by the American College of Emergency Physicians for their expertise in caring for geriatric patients, making Northwell the first health system in the country to achieve universal accreditation. 

A leader and advocate in data transparency and access, Dr. D’Angelo co-led a team to create Real-Time Actionable Data, a product that has increased visibility of operational data to leaders and frontline staff in many clinical and operational arenas across Northwell; a solution that went on to earn Northwell’s top innovation award in 2019. 

Dr. D’Angelo has served as the Chair for the Northwell Health Physician Partners Board of Governors & Executive Committee since 2019. He is also an Associate Professor of Emergency Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. 

Michael Dowling is one of the health care industry’s most highly respected voices, achieving the No. 1 ranking in Modern Healthcare magazine’s 2022 list of the “100 Most Influential People in Healthcare.” As a health care executive over the past three decades, he has been a no-excuses advocate for reforms that have helped the industry become more patient-focused and committed to quality and safety. His willingness to take a stand on societal issues such as gun violence and immigration has earned widespread praise and recognition from peers and the news media. During his years in academia and government, Mr. Dowling has distinguished himself as a compassionate voice for those in need, developing and promoting innovative health and human services policies. 

As president and CEO of Northwell Health for 22 years, he has demonstrated invaluable leadership in overseeing a rapidly expanding clinical, research and academic enterprise with annual revenue of $18 billion. With a workforce of more than 85,000, Northwell is the largest health care provider and private employer in New York State, caring for more than two million people annually through a vast network of 21 hospitals, more than 900 outpatient facilities—including 220 primary care practices and 50-plus urgent care centers—along with home care, rehabilitation and end-of-life services. 

Hailing from Ireland, Mr. Dowling bridges borders and brings a global perspective to health care. In 2020, he received the Presidential Distinguished Service Award for the Irish Abroad, which recognized his contributions to Ireland and to Irish communities abroad, presented by the President of Ireland. He also received an honorary fellowship of the Royal College of Physicians of Ireland and is a board member of the Foreign Policy Association. He is a member of the Institute of Medicine of the National Academies of Science, and the North American Board of the Smurfit School of Business at University College in Dublin, Ireland. He also earned his bachelor’s degree from University College Cork, and went on to receive honorary doctorates from Queens University Belfast and University College Dublin. Mr. Dowling was the Grand Marshal of New York City’s St. Patrick’s Day Parade in 2017, when he was also inducted into the Irish America Hall of Fame. 

Mr. Dowling has invested heavily in Northwell’s research arm, the Feinstein Institutes for Medical Research, home to 50 research labs, 3,000 clinical research trials, and 5,000 scientists and staff who are transforming the treatment of conditions like lupus, arthritis, sepsis, cancer, psychiatric illness and Alzheimer’s disease. Feinstein has gained stature as the global headquarters of bioelectronic medicine research, where physician scientists are tapping neural pathways that signal the body to heal itself, reducing reliance on prescription drugs. 

Under Mr. Dowling’s leadership, Northwell has also pursued a visionary approach to medical education, developing innovative curricula at its Zucker School of Medicine and the Hofstra Northwell School of Nursing and Physician Assistant Studies. Northwell’s graduate medical education programs have become one of the nation’s largest, training more than 1,900 medical residents and fellows annually. Further underscoring his commitment to education, Mr. Dowling’s first act when becoming Northwell’s CEO in 2002 was creating a corporate university, the Center for Learning & Innovation, which has helped instill a culture of lifelong learning among employees at all levels of the organization. 

Mr. Dowling’s highly visible leadership style enabled the health system to successfully navigate the intense challenges of the COVID-19 pandemic, most notably in 2020 when the New York metropolitan area was at the epicenter of the epidemic’s first wave. Mr. Dowling detailed his and Northwell’s experiences in a book titled Leading Through a Pandemic: The Inside Story of Humanity, Innovation, and Lessons Learned During the COVID-19 Crisis. 

Northwell clinicians treated more than 350,000 COVID patients and the health system used its innovative culture to significantly expand bed capacity and leverage its resources to ensure adequate supplies of lifesaving drugs, ventilators, personal protective equipment and other essential provisions to protect patients and caregivers, including administering the nation’s first COVID vaccines in December 2020. 

In addition to his 2020 book about Northwell’s response to the COVID-19 pandemic, Mr. Dowling is the co-author of a 2020 memoir titled After the Roof Caved In: An Immigrant’s Journey from Ireland to America, which chronicles his poverty-stricken childhood in Ireland, his years as a social policy expert in academia and in New York State government, and his ascent to becoming one of the health care industry’s preeminent leaders. He is also the co-author of the 2018 book, Health Care Reboot: Megatrends Energizing American Medicine, about the trends that are driving the nation’s health care system toward greater quality, safety, access and affordability. 

Prior to becoming CEO, Mr. Dowling was the health system’s executive vice president and chief operating officer, playing a key role in initiating mergers and acquisitions that enabled Northwell to become New York’s largest integrated health system. Before joining Northwell in 1995, he was a senior vice president at Empire Blue Cross/Blue Shield. Mr. Dowling served in New York State government for 12 years during the 1980s and early 1990s, including seven years as deputy secretary of human services to former New York Governor Mario Cuomo, state director of health, education and human services, and later, commissioner of the New York State Department of Social Services. He initiated numerous innovative programs aimed at expanding primary care access to the medically underserved and uninsured, and helping the state to combat the crack cocaine epidemic at that time. 

Before his public service career, Mr. Dowling was a professor of social policy and assistant dean at the Fordham University Graduate School of Social Services, and director of the Fordham campus in Westchester County. He was also a former instructor at the Harvard School of Public Health Center for Continuing Professional Education. 

Mr. Dowling has been honored with many awards and recognitions throughout his career, including: The Conference Board’s 2023 Committee for Economic Development Distinguished Leadership Award, the 2021 Glassdoor Employees’ Choice Award, the Columbia University School of Business’ 2020 Deming Cup for Operational Excellence, the 2012 B’nai B’rith National Healthcare Award, the National Center for Healthcare Leadership’s 2011 Gail L. Warden Leadership Excellence Award, the Healthcare Information and Management Systems’ 2011 CEO IT Achievement Award, the Ellis Island Honors Society’s 2007 Medal of Honor, the Foreign Policy Association Medal, the American Jewish Committee’s National Human Relations Award, the State University of New York’s Nelson A. Rockefeller College of Public Affairs and Policy’s Distinguished Public Service Award, the Mental Health Association of New York State’s Outstanding Public Service Award, and the American Society for Public Administration’s Alfred E. Smith Award. 

Mr. Dowling is a member of the National Center for Healthcare Leadership, the Greater New York Hospital Association, the Healthcare Association of New York State (HANYS), the League of Voluntary Hospitals of New York, the Institute for Healthcare Improvement (IHI), The Healthcare Institute and the Long Island Association and many other professional organizations. 

Dr. Kalman received her bachelor’s degree in art history from the University of Pennsylvania and medical degree from the Mount Sinai School of Medicine. She performed all her clinical training (internal medicine residency, chief medical residency, clinical cardiology, advanced heart failure) at Mount Sinai, New York. She has also completed a physician leadership course at the Health Management Academy and a health care delivery executive program at the Harvard University School of Business. Dr. Kalman began her professional career as an academic cardiologist, directing clinical and research heart failure programs at Beth Israel Medical Center, Tisch Hospital at New York University, and Mount Sinai Medical Center. In addition to her outstanding clinical skills and dedication to patients, Dr. Kalman was tremendously effective in organizing and galvanizing clinical, research, and administration to build programs focused on the needs of complex patients with advanced heart failure.  

She came to Northwell Health in 2014 as associate medical director of Long Island Jewish Medical Center and the North Shore LIJ Health System. She then moved to Lenox Hill Hospital as medical director (2015-2018) and was also health system’s medical director of patient experience (2016-2021). In 2018, Dr. Kalman became executive director of Lenox Hill Hospital and showed exemplary leadership during the pandemic.  

In 2021, she was appointed chief medical officer and deputy physician-in-chief at Northwell Health. Dr. Kalman is truly a visionary leader, a problem-solver, a connector, and a strategic mind. She is a professor of cardiology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.  

She is a well-recognized, highly respected national health care trailblazer and has helped put Northwell on the national map in many areas, including patient experience, crisis management, and effective change. 

Doug Kelly, MD became Deputy Director and Chief Scientist at the FDA’s device, diagnostics and digital health branch in 2020 after a 30-year seed and early-stage life sciences venture capital career starting, financing, growing and exiting companies spanning biotech, medical devices, robotics, laboratory tools, healthcare IT, ADME/Tox simulation and clinical trial software. At CDRH, Doug is the interface between the FDA and patient and physician groups, payors, industry, academia, innovators, investors, and other agencies and governments. His focus is on creating a more vibrant and sustainable MedTech ecosystem, to bring new innovations to patients faster to relieve suffering, especially in unserved and underserved populations.  

Doug received his BA in Biochemistry and Cell Biology with honors from University of California, San Diego, his MD from the Albert Einstein College of Medicine, and his MBA at the Stanford University Graduate School of Business. In addition to lecturing at the GSB and Stanford Medical School, he conceived of and taught the class “Financing The Start-up”, for over a decade the Stanford’s Department of Continuing Education biggest and most popular class. 

Arvind Krishna is the Chairman and Chief Executive Officer of IBM. As a business leader and technologist, he has led the building and expansion of new markets for IBM in artificial intelligence, cloud, quantum computing, and blockchain. He has also played a significant role in the development of innovative IBM products and solutions based on these emerging technologies. 

Over his 30-year career at IBM, Arvind led a series of bold transformations and delivered proven business results. He most recently drove the successful USD 34 billion acquisition of Red Hat – the largest software acquisition – that has defined the hybrid cloud market. Together, IBM and Red Hat give clients the unique ability to build mission-critical applications once and run them anywhere. 

Arvind previously was senior vice president of Cloud and Cognitive Software, where he pioneered the company’s hybrid cloud business, transformed IBM’s entire software and services portfolio and offerings for cloud, and grew the business. He also headed IBM Research, where he drove innovation in core and emerging technologies including artificial intelligence, quantum computing, blockchain, cloud platform services, data-driven solutions, and nanotechnology. In 2016, Wired Magazine selected Arvind as “one of 25 geniuses who are creating the future of business” for his foundational work on blockchain. 

As general manager of IBM Systems and Technology Group’s development and manufacturing organization, Arvind led the strategy for data-centric systems and the widespread industry adoption of open and collaborative technology standards. He also grew the IBM Information Management business by 50 percent. 

At IBM, Arvind has been an outspoken advocate for learning at every stage of one’s career. He has made scientific contributions in a number of technical fields, including wireless networking, security, systems, and databases. In addition, he founded IBM’s security software business and helped create the world’s first commercial wireless system.

Arvind is a member of the Board of Directors of the New York Federal Reserve Bank, and he serves on the Board of Directors of Northrop Grumman and the US-India Strategic Partnership Forum. Arvind has an undergraduate degree from the Indian Institute of Technology, Kanpur (IITK) and a Ph.D. from the University of Illinois at Urbana-Champaign. He is the recipient of distinguished alumni awards from both institutions. 

Dr. Geoffrey Ling is a pharmacologist and physician and co-founder of On Demand Pharmaceuticals. Clinically, he is a professor of neurology, neurosurgery and anesthesiology and critical care medicine at Johns Hopkins University and the Uniformed Services University of the Health Sciences, and an attending neuro critical care physician at Johns Hopkins Hospital. He serves as the Chair of the Veterans Administration’s National Research Advisory Council.

Dr. Ling is a retired U.S. Army colonel after 21 years on active duty. He served as an intensive care physician with the 452nd CSH (combat support hospital) in OEF-Afghanistan (2003) and 86th CSH and 10th CSH in OIF-Iraq (2005). Also, COL Ling has had four in-theater missions as a member of the Joint Chiefs of Staff “Gray Team” to assess traumatic brain injury (TBI) care in both combat theaters (2009, 2011). The 10th CSH named him their first “Physician of the Month.” Dr. Ling was also a “requested by name” consultant to Congresswoman Gabby Gifford’s trauma team following her tragic attack.

He was the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA), where he was previously a program manager and Deputy Director of the Defense Sciences Office. He served as an Assistant Director in the Science Division of President Obama’s White House Office of Science, Technology and Policy (OSTP). His BA with honors is from Washington University in St. Louis, MD from Georgetown University (elected to AOA) and his PhD in neuropharmacology is from Cornell University. He completed his neurology residency at Walter Reed Army Medical Center, neuro critical care fellowship at Johns Hopkins and research fellowship in neuropharmacology at the Memorial Sloan Kettering Cancer Center. He is board certified in both neurology and neuro critical care. He has published more than 200 peer-reviewed articles and book chapters.

Ellen Lukens is the Deputy Director of the Center for Medicare and Medicaid Innovation (CMS Innovation Center). In this role, Ms. Lukens leads policy development at the CMS Innovation Center. Ms. Lukens has deep experience both within and outside the government tackling complex health policy issues. Prior to this role, Ellen served as the Group Director of the Policy and Programs Group (PPG) within the CMS Innovation Center, where she led the team that provides cross-cutting support for Center-wide policy and portfolio management, including related to the Advanced Payment Model (APM) portion of the Medicare and Children’s Health Insurance Program Reauthorization Act of 2015 (MACRA). Ms. Lukens also served as the Division Director for Ambulatory Payment models, where she led development of specialty care models, including the Oncology Care Model. Prior to joining CMS, Ms. Lukens led the Provider Practice at Avalere Health. In that role, she worked with hospitals, physician groups, and post-acute care providers on many policy and strategy issues, including developing analytic tools to improve performance and to evaluate participation in CMMI models. Prior to Avalere, Ms. Lukens held policy roles in hospital associations. Ms. Lukens began her health policy career as Presidential Management Fellow at CMS. She earned her bachelor’s degree from Northwestern University and a Masters in Public Health from the University of Michigan. 

Tyler Mathisen co-anchors CNBC’s “Power Lunch” (M-F, 2PM-3PM ET), one of the network’s longest running program franchises. He is also Vice President, Events Strategy for CNBC, working closely with the network’s events team to grow the rapidly expanding business. 

Previously, Mathisen was co-anchor of “Nightly Business Report,” an award-winning evening business news program produced by CNBC for U.S. public television. In 2014, NBR was named best radio/TV show by the Society of American Business Editors and Writers (SABEW). Since joining CNBC in 1997, Mathisen has held a number of positions including managing editor of CNBC Business News, responsible for directing the network’s daily content and coverage. He was also co-anchor of CNBC’s “Closing Bell.” 

Mathisen has reported one-hour documentaries for the network including “Best Buy: The Big Box Fights Back,” “Supermarkets Inc: Inside a $500 Billion Money Machine” and “Death: It’s a Living.” Mathisen was also host of the CNBC series “How I Made My Millions.”

Prior to CNBC, Mathisen spent 15 years as a writer, senior editor and top editor for Money magazine. Among other duties, he supervised the magazine’s mutual funds coverage, its annual investment forecast issue and its expansion into electronic journalism, for which it won the first-ever National Magazine Award for New Media in 1997.

In 1993, Mathisen won the American University-Investment Company Institute Award for Personal Finance Journalism for a televised series on “Caring for Aging Parents,” which aired on ABC’s “Good Morning America.” Mathisen served as money editor of “GMA” from 1991 to 1997. He also won an Emmy Award for a report on the 1987 stock market crash that aired on New York’s WCBS-TV. 

A native of Arlington, Va., Mathisen graduated with distinction from the University of Virginia. 

Mark H. Michalski, MD is the CEO of Ascertain, a healthcare AI company bringing best-in-class automation tech to healthcare enterprise operations. He previously held roles as worldwide Head Healthcare & Life Sciences AI/ML BD and Head of Strategic BD at Amazon/AWS. Dr. Michalski was faculty at Harvard Medical School, where he launched the Center for Clinical Data Science (CCDS)—-a research center of excellence embedded within the world-class Mass Gen Brigham provider system. The CCDS launched over a dozen AI/ML solutions through strategic partnerships with GE, Nvidia, Nuance, and Fuji to commercialize its technology. 

Dr. Michalski has held leadership and operational roles at early-stage companies in the medical software and device domain, including Butterfly Network (a point-of-care ultrasound company) as president and CMO and Hyperfine Research (a portable MRI system company) as CMO. Both organizations successfully went public in 2021. Dr. Michalski has also worked at the intersection of technology and drug development, working with global biopharma clients as the AI/ML practice lead at Headland Strategy Group, and held additional life science-focused roles at Google and Genentech. 

Dr. Michalski completed his radiology residency training as a Holman Fellow at Yale-New Haven Hospital. He graduated with a degree in Cybernetics from the University of California at Los Angeles with multiple honors and received his medical degree from Stanford University. 

Joseph Moscola, PA, MBA, is executive vice president, enterprise services for Northwell Health. In this role, Joe will lead several critical functions that drive the organization and the care our team members provide, including human resources, information technology, facilities & construction, real estate, and shared services administration. In addition, he will be responsible for leading strategic business initiatives that are driving new revenue streams for the health system, including FlexStaff and Northwell Direct and further integrating learning and development for clinical and non-clinical team members into our people strategy. 

Previously, Mr. Moscola served as chief human resources officer and drove the creation and successful launch of our employee promise, refreshed values, and the Northwell Career Experience, which helps team members learn, grow and thrive in the organization. He also led Human Resources’ highly effective pandemic response, which focused on supporting the intense staffing needs of the organization, and the emotional, psychological and physical well-being needs of our team members. 

Mr. Moscola also previously served as senior vice president and executive director of Ambulatory Operations. In this role, he oversaw the $1.1 billion ambulatory operation, working with clinical and administrative service line leadership, Northwell Health Physician Partners and clinical joint ventures. 

He began his career as a physician assistant in cardiothoracic surgery and later transitioned to an administrative career, serving as administrative director for neuroscience at South Shore University Hospital, then senior administrative director of neurology and neurosurgery at North Shore University Hospital and Long Island Jewish Medical Center. 

Holding a bachelor’s degree from St. John’s University, Mr. Moscola earned an MBA from Adelphi University and a physician assistant certificate from Catholic Medical Centers-Bayley Seton Campus. He also graduated as a Fellow of the Health Management Academy. 

Aside from his executive role at Northwell, Mr. Moscola serves on the Board of Directors for Farmingdale State College and Nassau Community College, and he is a trustee of the 1199 Pension Fund serving employees for the New York Region. 

Darilyn V. Moyer, MD, MACP, FRCP, FIDSA, FAMWA, FEFIM, is the Executive Vice President and Chief Executive Officer of the American College of Physicians (ACP).

Board certified in internal medicine and infectious diseases, Dr. Moyer was elected into Mastership (MACP) in ACP in 2022, which recognizes outstanding and extraordinary career accomplishments. Prior to that she was awarded Fellowship in ACP, an honorary designation that recognizes ongoing individual service and contributions to the practice of medicine. She serves on ACP’s Board of Regents, which manages the business and affairs of ACP and is the main policy-making body of the College, chaired ACP’s Board of Governors, and served as Governor of ACP’s Pennsylvania Southeastern Chapter. She is a Founding Board Member of the Gender Equity in Medicine and Science (GEMS) Alliance, Past President of Council of Medical Subspecialty Societies and former member of the Board of Directors, and Immediate Past Chair of the Board of Directors for the Primary Care Collaborative and is a member of Women of Impact. Dr. Moyer is the recipient of the American Medical Women’s Association (AMWA) 2023 Inspire Award, the American Medical Association (AMA) Women Physicians Section (WPS) 2022 Inspiration Award and the Thomas Jefferson University Hospital Courage to Heal 2021 Award. She is also a recipient of the 2020 American Medical Women’s Association Elizabeth Blackwell Award, as well as the recipient of the 2020 Lewis Katz School of Medicine at Temple University Alumni Achievement Award.

Prior to becoming ACP’s EVP and CEO, Dr. Moyer was a Professor of Medicine, Executive Vice Chair for Education in the Department of Medicine, Internal Medicine Residency Program Director and Assistant Dean for Graduate Medical Education at Lewis Katz School of Medicine at Temple University. She was previously the Co-Faculty Advisor for the Temple University School of Medicine Internal Medicine Interest Group and for the Temple University School of Medicine Student Educating About Healthcare Policy Group. She received the Temple University School of Medicine Women in Medicine Mentoring Award in 2012.

Dr. Moyer’s research and scholarly activity interests and presentations have been in the areas of medical education, high value care, patient safety, professionalism and digital media, gender equity, and HIV/infectious diseases.

She received her Bachelor of Arts degree in the Biological Basis of Behavior, Biology and Psychology from the University of Pennsylvania and attended medical school at Temple University School of Medicine. She completed her internal medicine residency at Temple University Hospital and served as a Chief Resident/Clinical Instructor of Medicine. She went on to complete an Infectious Diseases Fellowship at Harbor-UCLA Medical Center in Torrance, CA. Dr. Moyer currently practices part time at the Temple University Internal Medicine Associates.

Mary Varghese Presti is a senior healthcare technology executive with over 25 years of experience leading growth and innovation in public and privately held healthcare technology and life sciences companies worldwide. Mary’s career reflects a demonstrated track record in leading breakthrough strategies focused on the healthcare industry: digitization in healthcare using advanced AI technologies, scaling software businesses internationally, transforming commercial models in complex, global companies, and delivering year over year double digit growth through strong P+L management. 

Currently, Mary leads the Portfolio Evolution and Incubation unit for Microsoft’s Health & Life Sciences Division.  In this role Mary is focused on development of generative AI-based clinical workflow and productivity tools serving a vibrant and scaled healthcare ecosystem.  Her scope spans physician, nurse, clinical coding and revenue cycle personas.  Prior to this, Mary served as SVP and GM of Dragon Medical at Nuance, where she was responsible for a global P+L exceeding $600M while incubating a de novo ambient solution for the Nursing workforce.  Mary started her career as a pediatric nurse at Johns Hopkins, and leveraged that clinical experience as a touchstone as she moved through a decade in management consulting solving hard problems in healthcare across the US, to Pfizer where she redesigned their commercial model in response to health reform and the proliferation of digital health and real world data. 

Mary was recognized in 2020 by the Healthcare Businesswomen’s Association as a Healthcare Luminary and received the Alumni Award for Innovation Practice in 2022 by the University of Pennsylvania School of Nursing. 

She received her bachelor’s degree in Nursing from the University of Pennsylvania and her master’s degree in Health Policy from Johns Hopkins University. 

Murthy Simhambhatla joined SetPoint Medical from Evolus, a medical aesthetics company with a lead biologic drug, DWP‐450, which he led towards an IPO in 2018. Prior to Evolus, Murthy was Senior Vice President at Abbott Laboratories and President of Abbott Medical Optics (AMO), a $1B‐plus global ophthalmic business focused on cataract and refractive surgery.

Prior to AMO, Murthy led the Ibis Biosciences molecular diagnostics business at Abbott. He joined Ibis after leading Abbott Vascular’s commercial operations in Australia and New Zealand. Murthy joined Abbott through the acquisition of Guidant’s vascular business, where he led the development of the Xience V® Drug Eluting Stent, which remains the leading vascular stent platform globally.

Murthy has M.S. and Ph.D. degrees in Polymer Engineering from the University of Akron and a bachelor’s degree in Chemical Engineering from Anna University in India.

Kevin J. Tracey, is President and CEO and the Karches Family Distinguished Chair in Medical Research at The Feinstein Institutes for Medical Research; Professor of Neurosurgery and Molecular Medicine at the Zucker School of Medicine at Hofstra-Northwell; and Executive Vice President, Research, at Northwell Health, in New York. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping neural circuits controlling immunity and identifying the therapeutic action of monoclonal anti-TNF antibodies.

Professor Tracey received his B.S. (Chemistry, summa cum laude, Phi Beta Kappa) from Boston College in 1979, and his M.D. from Boston University in 1983.  He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to The Feinstein Institutes.

An inventor with more than 75 United States patents, author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of >1 million sepsis caregivers in more than 70 countries. His honors and awards include a Doctorates honoris causa from the Karolinska Institute, Stockholm, Sweden, the University of Fribourg, Switzerland and Hofstra University, New York; the Boston University Distinguished Alumni Award; Fellow of the AIMBE Class (2020), the Harvey Society lecture, New York; and lectureships from Harvard, Yale, Rockefeller University, the NIH, and elsewhere. His memberships include the American Society of Clinical Investigation (2001), the American Association of Physicians (2009), the Long Island Technology Hall of Fame (2012), Alpha Omega Alpha (2014), the American Association for the Advancement of Science (2014), and the American Institute for Medical and Biological Engineering (2020). Professor Tracey is author of Fatal Sequence (Dana Press), and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.

Craig Venter, PhD, is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is founder, chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 120 scientists and staff dedicated to human, microbial, synthetic, and environmental genomic research, and the exploration of social and ethical issues in genomics.

Dr. Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in biochemistry and a PhD in physiology and pharmacology from the University of California at San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed expressed sequence tags or ESTs, a revolutionary new strategy for rapid gene discovery. 

In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using the new whole genome shotgun technique. 

In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse, and rat genomes. 

Dr. Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in constructing the first self-replicating bacterial cell using synthetic DNA. 

Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology. 

Dr. Venter is also a serial entrepreneur who has co-founded several companies including  Synthetic Genomics, Inc., now Viridos and Human Longevity, Inc. (HLI). 

Deborah is an investor at Cerity Partners Ventures, a multi-sector, multi-stage venture capital group that partners with about 20 corporations globally to establish and manage their corporate venture capital programs in healthcare, food and agriculture, industrial, tech, and the built world. Cerity Partners Ventures was formed when Touchdown Ventures merged with Cerity Partners. 

At Touchdown Ventures, Deborah co-founded five corporate venture programs and its healthcare practice, investing in digital, diagnostic, device, and pharma tech startups, while helping scale the firm.  

Before joining Touchdown, Deborah spent a decade at GE Ventures and GE Corporate investing in and building businesses, helping to create “what’s next” through investment, partnerships, innovation, and corporate development. Deborah helped launch startups and guide technology from the lab to the market at GE and Columbia University, backed by her operating experience at GE and Celarix.com. Deborah began her career in management consulting at Andersen.  

Deborah earned her MBA concentrating in Finance and Entrepreneurship from NYU’s Stern School of Business and her BS and BA from Lehigh University, where she has served as Trustee and founding Advisor to the nationally-ranked Baker Institute for Entrepreneurship, Creativity, and Innovation.  She has supported entrepreneurs and emerging investors through Springboard Enterprises, TechStars, DreamIt Ventures, HSBUvc Labs, Leslie eLab, MedTech Innovator, the WEF, and others.